Diabetic nephropathy in type 1 diabetes: a review of early natural history, pathogenesis, and diagnosis

Diabetes/Metabolism Research and Reviews

Volumn 33, Issue 2, 2017, Pages

  Papadopoulou Marketou, Nektaria ^a,b   Chrousos, George P ^a   Kanaka Gantenbein, Christina ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHITINASE 3 LIKE PROTEIN 1; CYSTATIN C; GELATINASE; GROWTH DIFFERENTIATION FACTOR 15; LIPOCALIN;

DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE COURSE; DYSLIPIDEMIA; GENETIC SUSCEPTIBILITY; GLYCEMIC CONTROL; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY ARTERY STENOSIS; KIDNEY PAPILLA NECROSIS; KIDNEY TUBULE ACIDOSIS; MACROALBUMINURIA; MICROALBUMINURIA; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; REMISSION; REVIEW; SMOKING; COMPLICATION; DIABETIC NEPHROPATHIES; METABOLISM;

BIOMARKERS; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; HUMANS;

EID: 84990206435     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2841     Document Type: Review

References (90)

1. Kilpatrick ES. The rise and fall of HbA(1c) as a risk marker for diabetes complications. Diabetologia. 2012;55:2089–2091.
2. Mogensen CE. How to protect the kidney in diabetic patients: with special reference to IDDM. Diabetes. 1997;46(Suppl 2):S104–S111.
3. Nathan DM. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37:9–16.
4. Zhang L, Chen B, Tang L. Metabolic memory: mechanisms and implications for diabetic retinopathy. Diabetes Res Clin Pract. 2012;96:286–293.
5. Lachin JM, Orchard TJ, Nathan DM. Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37:39–43.
6. Schoenaker DAJM, Simon D, Chaturvedi N, Fuller JH, Soedamah-Muthu SS. Glycemic control and all-cause mortality risk in type 1 diabetes patients: the EURODIAB prospective complications study. J Clin Endocrinol Metab. 2014;99:800–817.
7. Iyengar SK, Abboud HE, Goddard KAB, et al. Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations. 2007;56:1577–1585.
8. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med. 1989;320:1161–1165.
9. Palmer ND, Freedman BI. Insights into the genetic architecture of diabetic nephropathy. Curr Diab Rep. 2012;12:423–431.
10. Nin JW, Jorsal A, Ferreira I, et al. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care. 2011;34:442–447.
11. Sawicki PT, Didjurgeit U, Mühlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care. 1994;17:126–131.
12. Thorn LM, Gordin D, Harjutsalo V, et al. The presence and consequence of nonalbuminuric chronic kidney disease in patients with type 1 diabetes. Diabetes Care. 2015;38:2128–2133.
13. Parving HH, Oxenbøll B, Svendsen PA, Christiansen JS, Andersen AR. Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion. Acta Endocrinol. 1982;100:550–555.
14. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med. 1984;311:89–93.
15. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet. 1982;1:1430–1432.
16. Williams ME. Diabetic nephropathy: the proteinuria hypothesis. Am J Nephrol. 25:77–94.
17. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med. 2001;134:370–379.
18. Amin R, Widmer B, Prevost AT, et al. Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: prospective observational study. BMJ. 2008;336:697–701.
19. Raile K, Galler A, Hofer S, et al. Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. Diabetes Care. 2007;30:2523–2528.
20. Perkins BA, Krolewski AS. Early nephropathy in type 1 diabetes: a new perspective on who will and who will not progress. Curr Diab Rep. 2005;5:455–463.
21. Perkins BA, Krolewski AS. Early nephropathy in type 1 diabetes: the importance of early renal function decline. Curr Opin Nephrol Hypertens. 2009;18:233–240.
22. Rosolowsky ET, Niewczas MA, Ficociello LH, Perkins BA, Warram JH, Krolewski AS. Between hyperfiltration and impairment: demystifying early renal functional changes in diabetic nephropathy. Diabetes Res Clin Pract. 2008;82(Suppl 1):S46–S53.
23. Hsu C-Y, Chertow GM, Curhan GC. Methodological issues in studying the epidemiology of mild to moderate chronic renal insufficiency. Kidney Int. 2002;61:1567–1576.
24. Uhlig K, Eckardt K-U. A decade after the KDOQI CKD guidelines: impact on CKD guidelines. Am J Kidney Dis. 2012;60:705–706.
25. Parving HH, Hommel E, Mathiesen E, et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. Br Med J (Clin Res Ed). 1988;296:156–160.
26. M Shlomo, KS Polonsky, PR Larsen, and HM Kronenberg. Williams Textbook of Endocrinology, 12th edition. 2011. Philadelphia: Saunders.
27. Pezzolesi MG, Poznik GD, Mychaleckyj JC, et al. Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1. Diabetes. 2009;58:1403–1410.
28. Sandholm N, Salem RM, McKnight AJ, et al. New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet. 2012;8: e1002921
29. Thrailkill KM, Moreau CS, Cockrell GE, et al. Disease and gender-specific dysregulation of NGAL and MMP-9 in type 1 diabetes mellitus. Endocrine. 2010;37:336–343.
30. Kure M, Pezzolesi MG, Poznik GD, et al. Genetic variation in the matrix metalloproteinase genes and diabetic nephropathy in type 1 diabetes. Mol Genet Metab. 2011;103:60–65.
31. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381–389. doi: 10.1056/NEJM200002103420603
32. Al-Kafaji G, Golbahar J. High glucose-induced oxidative stress increases the copy number of mitochondrial DNA in human mesangial cells. Biomed Res Int. 2013;2013:754946
33. Oldfield MD, Bach LA, Forbes JM, et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products RAGE. J Clin Invest. 2001;108:1853–1863.
34. Thallas-Bonke V, Cooper ME. Tandem inhibition of PKC in diabetic nephropathy: it takes two to tango? Diabetes. 2013;62:1010–1011.
35. Ichihara A, Suzuki F, Nakagawa T, et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol. 2006;17:1950–1961.
36. Saraheimo M, Teppo A-M, Forsblom C, Fagerudd J, Groop P-H. Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia. 2003;46:1402–1407.
37. Hansen TK, Forsblom C, Saraheimo M, et al. Association between mannose-binding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes. Diabetologia. 2010;53:1517–1524.
38. Carranza K, Veron D, Cercado A, et al. Cellular and molecular aspects of diabetic nephropathy; the role of VEGF-A. Nefrol Publicación of La Soc Española Nefrol. 2015;35:131–138.
39. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983;32(Suppl 2):64–78.
40. Thomson SC, Vallon V, Blantz RC. Kidney function in early diabetes: the tubular hypothesis of glomerular filtration. Am J Physiol Renal Physiol. 2004;286:F8–F15.
41. Ellis EN, Warady BA, Wood EG, et al. Renal structural-functional relationships in early diabetes mellitus. Pediatr Nephrol. 1997;11:584–591.
42. Mauer SM, Steffes MW, Ellis EN, Sutherland DER, Brown DM, Goetz FC. Structural-functional relationships in diabetic nephropathy. J Clin Invest. 1984;74:1143–1155.
43. Drummond K, Mauer M. The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes. 2002;51:1580–1587.
44. Steinke JM, Sinaiko AR, Kramer MS, et al. The early natural history of nephropathy in type 1. 2005;54
45. Poulsen PL, Hansen KW, Mogensen CE. Ambulatory blood pressure in the transition from normo- to microalbuminuria. A longitudinal study in IDDM patients. Diabetes. 1994;43:1248–1253.
46. Mogensen CE, Keane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet. 1995;346:1080–1084.
47. Steinke JM, Sinaiko AR, Kramer MS, Suissa S, Chavers BM, Mauer M. The early natural history of nephropathy in type 1 diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes. 2005;54:2164–2171.
48. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003;348:2285–2293.
49. Nauta FL, Boertien WE, Bakker SJL, et al. Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care. 2011;34:975–981.
50. Torbjörnsdotter TB, Perrin NESS, Jaremko GA, Berg UB. Widening of foot processes in normoalbuminuric adolescents with type 1 diabetes. Pediatr Nephrol. 2005;20:750–758. doi: 10.1007/s00467-005-1829-5
51. Drummond KN, Kramer MS, Suissa S, et al. Effects of duration and age at onset of type 1 diabetes on preclinical manifestations of nephropathy. Diabetes. 2003;52:1818–1824.
52. Demirel F, Tepe D, Kara O, Esen I. Microvascular complications in adolescents with type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol. 2013;5:145–149.
53. Parving HH, Andersen AR, Smidt UM, Oxenbøll B, Edsberg B, Christiansen JS. Diabetic nephropathy and arterial hypertension. Diabetologia. 1983;24:10–12.
54. Mauer M, Fioretto P. Pancreas transplantation and reversal of diabetic nephropathy lesions. Med Clin North Am. 2013;97:109–114.
55. Fioretto P, Mauer M. Reversal of diabetic nephropathy: lessons from pancreas transplantation. J Nephrol. 25:13–18.
56. Pavenstädt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev. 2003;83:253–307.
57. Steffes MW, Schmidt D, McCrery R, Basgen JM. Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int. 2001;59:2104–2113.
58. White KE, Bilous RW, Marshall SM, et al. Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes. 2002;51:3083–3089.
59. Najafian B, Crosson JT, Kim Y, Mauer M. Glomerulotubular junction abnormalities are associated with proteinuria in type 1 diabetes. J Am Soc Nephrol. 2006;17:S53–S60.
60. Thomas MC, Burns WC, Cooper ME. Tubular changes in early diabetic nephropathy. Adv Chronic Kidney Dis. 2005;12:177–176.
61. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int. 1999;56:1627–1637.
62. Tervaert TWC, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21:556–563.
63. Salifu MO, Haria DM, Badero O, Aytug S, McFarlane SI. Challenges in the diagnosis and management of renal artery stenosis. Curr Hypertens Rep. 2005;7:219–227.
64. Hricik DE, Browning PJ, Kopelman R, Goorno WE, Madias NE, Dzau VJ. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. N Engl J Med. 1983;308:373–376.
65. Griffin MD, Bergstralhn EJ, Larson TS. Renal papillary necrosis—a sixteen-year clinical experience. J Am Soc Nephrol. 1995;6:248–256.
66. Kelly DJ, Wilkinson-Berka JL, Allen TJ, Cooper ME, Skinner SLA. new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat TGR. Kidney Int. 1998;54:343–352.
67. Mnif MF, Kamoun M, Kacem FH, et al. Complicated urinary tract infections associated with diabetes mellitus: pathogenesis, diagnosis and management. Indian J Endocrinol Metab. 2013;17:442–445.
68. Lush DJ, King JA, Fray JC. Pathophysiology of low renin syndromes: sites of renal renin secretory impairment and prorenin overexpression. Kidney Int. 1993;43:983–999.
69. Thomson SC, Vallon V, Blantz RC. Kidney function in early diabetes: the tubular hypothesis of glomerular filtration. Am J Physiol Renal Physiol. 2004;286:F8–F15.
70. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease. Diabetes. 2005;54:1626–1634.
71. Papadopoulou-Marketou N, Skevaki C, Kosteria I, et al. NGAL and cystatin C: two possible early markers of diabetic nephropathy in young patients with type 1 diabetes mellitus: one year follow up. Hormones (Athens). 2014. doi: 10.14310/horm.2002.1520
72. Sakamoto F, Katakami N, Kaneto H, et al. Association of serum YKL-40 levels with urinary albumin excretion rate in young Japanese patients with type 1 diabetes mellitus. Endocr J. 2013;60:73–79.
73. Hellemons ME, Mazagova M, Gansevoort RT, et al. Growth-differentiation factor 15 predicts worsening of albuminuria in patients with type 2 diabetes. Diabetes Care. 2012;35:2340–2346.
74. Lacquaniti A, Donato V, Pintaudi B, et al. “Normoalbuminuric” diabetic nephropathy: tubular damage and NGAL. Acta Diabetol. 2013;50:935–942.
75. Chae H-W, Shin J-I, Kwon A-R, Kim H-S, Kim D-H. Spot urine albumin to creatinine ratio and serum cystatin C are effective for detection of diabetic nephropathy in childhood diabetic patients. J Korean Med Sci. 2012;27:784–787.
76. Lajer M, Jorsal A, Tarnow L, Parving H-H, Rossing P. Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetes Care. 2010;33:1567–1572.
77. Koulis C, Chow BSM, McKelvey M, et al. AT2R agonist, compound 21, is reno-protective against type 1 diabetic nephropathy. Hypertension. 2015;65:1073–1081.
78. Kohan DE, Barton M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int. 2014;86:896–904.
79. Icociello LIHF. Renal hyperfiltration and the development of microalbuminuria in type 1. Diabetes. 2009;32:8–12.
80. Comper WD, Osicka TM, Clark M, MacIsaac RJ, Jerums G. Earlier detection of microalbuminuria in diabetic patients using a new urinary albumin assay. Kidney Int. 2004;65:1850–1855.
81. Fagerudd JA, Groop PH, Honkanen E, Teppo AM, Grönhagen-Riska C. Urinary excretion of TGF-beta 1, PDGF-BB and fibronectin in insulin-dependent diabetes mellitus patients. Kidney Int Suppl. 1997;63:S195–S197.
82. Gerritsen KGF, Leeuwis JW, Koeners MP, et al. Elevated urinary connective tissue growth factor in diabetic nephropathy is caused by local production and tubular dysfunction. J Diabetes Res. 2015;2015:1–11.
83. Ito H, Fujita H, Takahashi T. Diagnostic biomarkers of diabetic nephropathy. Expert Opin Med Diagn. 2008;2:161–169.
84. Hong C-Y, Hughes K, Chia K-S, Ng V, Ling S-L. Urinary 1-microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapore. Diabetes Care. 2003;26:338–342.
85. Salem MAK, SA e-H, OM S, MMK e-T, PH T. Urinary excretion of n-acetyl-beta-d-glucosaminidase and retinol binding protein as alternative indicators of nephropathy in patients with type 1 diabetes mellitus. Pediatr Diabetes. 2002;3:37–41.
86. Rathcke CN, Persson F, Tarnow L, Rossing P, Vestergaard H. YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care. 2009;32:3238
87. Hawkins R. New biomarkers of acute kidney injury and the cardio-renal syndrome. Korean J Lab Med. 2011;31:72–80.
88. Malyszko J, Bachorzewska-Gajewska H, Malyszko J, Iaina-Levin N, Kobus G, Dobrzycki S. Markers of kidney function in the elderly in relation to the new CKD-EPI formula for estimation of glomerular filtration rate. Arch Med Sci. 2011;7:658–664.
89. Panduru NM, Forsblom C, Saraheimo M, et al. Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care. 2013;36:2077–2083.
90. Zheng M, Lv L-L, Ni J, et al. Urinary podocyte-associated mRNA profile in various stages of diabetic nephropathy. PLoS One. 2011;6 e20431